Arsenic salt-induced DNA damage and expression of mutant p53 and COX-2 proteins in SV-40 immortalized human uroepithelial cells

Mutagenesis

Volumn 22, Issue 6, 2007, Pages 403-408

  Chai, Chee Yin ^a,b,c   Huang, Ya Chun ^a   Hung, Wen Chun ^c   Kang, Wan Yi ^a,b   Chen, Wan Tzu ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENITE SODIUM; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MUTANT PROTEIN; PROTEIN P53;

ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CELL IMMORTALIZATION; CELL LINE; CHEMICAL CARCINOGENESIS; COMET ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; TOXICITY TESTING; WESTERN BLOTTING;

ARSENITES; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; CELL SURVIVAL; CELL TRANSFORMATION, VIRAL; COMET ASSAY; CYCLOOXYGENASE 2; DNA; DNA DAMAGE; HUMANS; SIMIAN VIRUS 40; SODIUM COMPOUNDS; SULFHYDRYL REAGENTS; TUMOR SUPPRESSOR PROTEIN P53; UROTHELIUM;

EID: 36049017653     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/gem035     Document Type: Article

References (82)

1. International Agency for Research on Cancer (IARC). (1980) Carcinogenesis of arsenic compounds. In IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 23, pp. 37-141, IARC, Lyon, France.
2. Wang, J. P., Qi, L., Moore, M. R. and Ng, J. C. (2002) A review of animal models for the study of arsenic carcinogenesis. Toxicol. Lett., 133, 17-31.
3. Jha, A. N., Noditi, M., Nilsson, R. and Natarajan, A. T. (1992) Genotoxic effects of sodium arsenite on human cells. Mutat. Res., 284, 215-221.
4. Tice, R. R., Yager, J. W., Andrews, P. and Crecelius, E. (1997) Effect of hepatic methyl donor status on urinary excretion and DNA damage in B6C3F1 mice treated with sodium arsenite. Mutat. Res., 386, 315-334.
5. Hughes, M. F. (2002) Arsenic toxicity and potential mechanisms of action. Toxicol. Lett., 133, 1-16.
6. Raisuddin, S. and Jha, A. N. (2004) Relative sensitivity of fish and mammalian cells to sodium arsenate and arsenite as determined by alkaline single-cell gel electrophoresis and cytokinesis-block micronucleus assay. Environ. Mol. Mutagen., 44, 83-89.
7. Forkner, C. and McNair-Scott, T. F. (1931) Arsenic as a therapeutic agent in chronic myeloid leukemia. J. Am. Med. Assoc., 97, 305-309.
8. Kandel, E. V. and Leroy, G. V. (1937) Chronic arsenical poisoning during the treatment of chronic myeloid leukemia. Arch. Intern. Med., 60, 846-866.
9. Konig, A., Wrazel, L., Warrell, R. P., Jr., Rivi, R., Pandolfi, P. P., Jakubowski, A. and Gabrilove, J. L. (1997) Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood, 90, 562-570.
10. Sanz, M. A., Fenaux, P. and Lo Coco, F. (2005) Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica, 90, 1231-1235.
11. Dong, J. T. and Luo, X. M. (1993) Arsenic-induced DNA-strand breaks associated with DNA-protein crosslinks in human fetal lung fibroblasts. Mutat. Res., 302, 97-102.
12. Lynn, S., Shiung, J. N., Gurr, J. R. and Jan, K. Y. (1998) Arsenite stimulates poly (ADP-ribosylation) by generation of nitric oxide. Free Radic. Biol. Med., 24, 442-449.
13. Schaumloffel, N. and Gebel, T. (1998) Heterogeneity of the DNA damage provoked by antimony and arsenic. Mutagenesis, 13, 281-286.
14. Schwartz, D. and Rotter, V. (1998) p53-dependent cell cycle control: response to genotoxic stress. Semin. Cancer Biol., 8, 325-336.
15. Sionov, R. V. and Haupt, Y. (1999) The cellular response to p53: the decision between life and death. Oncogene, 18, 6145-6157.
16. Bush, C., Price, P., Norton, J., Parkins, C. S., Bailey, M. J., Boyd, J., Jones, C. R., A'Hern, R. P. and Horwich, A. (1991) Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. Br. J. cancer, 64, 357-360.
17. Nakopoulou, L., Vourlakou, C., Zervas, A., Tzonou, A., Gakiopoulou, H. and Dimopoulos, M. A. (1998) The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum. Pathol., 29, 146-154.
18. Chen, C. J., Hsu, L. I., Wang, C. H. et al. (2005) Biomarkers of exposure, effect, and susceptibility of arsenic-induced health hazards in Taiwan. Toxicol. Appl. Pharmacol., 206, 198-206.
19. Chang, Y. W., Jakobi, R., McGinty, A., Foschi, M., Dunn, M. J. and Sorokin, A. (2000) Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol. Cell. Biol., 20, 8571-8579.
20. Dowd, N. P., Scully, M., Adderley, S. R., Cunningham, A. J. and Fitzgerald, D. J. (2001) Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J. Clin. Invest., 108, 585-590.
21. Han, J. A., Kim, J. I., Ongusaha, P. P., Hwang, D. H., Ballou, L. R., Mahale, A., Aaronson, S. A. and Lee, S. W. (2002) p53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J., 21, 5635-5644.
22. Yang, T., Huang, Y., Heasley, L. E., Berl, T., Schnermann, J. B. and Briggs, J. P. (2000) MAPK mediation of hypertonicity-stimulated cyclooxygenase-2 expression in renal medullary collecting duct cells. J. Biol. Chem., 275, 23281-23286.
23. Vainio, H. (2001) Is COX-2 inhibition a panacea for cancer prevention? Int. J. cancer, 94, 613-614.
24. Vanderveen, E. E., Grekin, R. C., Swanson, N. A. and Kragballe, K. (1986) Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern. Arch. dermatol., 122, 407-412.
25. Cuendet, M. and Pezzuto, J. M. (2000) The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol. Drug Interact., 17, 109-157.
26. Muller-Decker, K., Neufang, G., Berger, I., Neumann, M., Marks, F. and Furstenberger, G. (2002) Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc. Natl Acad. Sci. USA, 99, 12483-12488.
27. Rys-Sikora, K. E., Konger, R. L., Schoggins, J. W., Malaviya, R. and Pentland, A. P. (2000) Coordinate expression of secretory phospholipase A(2) and cyclooxygenase-2 in activated human keratinocytes. Am. J. Physiol. Cell Physiol., 278, C822-C833.
28. Hamadeh, H. K., Trouba, K. J., Amin, R. P., Afshari, C. A. and Germolec, D. (2002) Coordination of altered DNA repair and damage pathways in arsenite-exposed keratinocytes. Toxicol. Sci., 69, 306-316.
29. Su, P. F., Hu, Y. J., Ho, I. C., Cheng, Y. M. and Lee, T. C. (2006) Distinct gene expression profiles in immortalized human urothelial cells exposed to inorganic arsenite and its methylated trivalent metabolites. Environ. Health Perspect., 114, 394-403.
30. Americn Type Culture Collection. (1990) Product description of SV-HUC-1 http://www.atcc.org/common/catalog/numSearch/numResults.cfm?atccNum55CRL-9520, March 1, 2007.
31. Singh, N. P. and Wrenn, M. E. (1988) Determinations of actinides in biological and environmental samples. Sci. Total Environ., 70, 187-203.
32. Hartmann, A., Plappert, U., Poetter, F. and Suter, W. (2003) Comparative study with the alkaline comet assay and the chromosome aberration test. Mutat. Res., 536, 27-38.
33. Tice, R. R., Agurell, E., Anderson, D. et al. (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen., 35, 206-221.
34. Tice, R. R. and Strauss, G. H. (1995) The single cell gel electrophoresis/comet assay: a potential tool for detecting radiation-induced DNA damage in humans. Stem cells, 13 (Suppl. 1), 207-214.
35. 2 and gamma-irradiation with the alkaline comet assay. Mutat. Res., 383, 71-80.
36. Chen, S. C., Kao, C. M., Huang, M. H., Shih, M. K., Chen, Y. L., Huang, S. P. and Liu, T. Z. (2003) Assessment of genotoxicity of benzidine and its structural analogues to human lymphocytes using comet assay. Toxicol. Sci., 72, 283-288.
37. Asamoto, M., Mann, A. M., Macatee, T. L. and Cohen, S. M. (1994) Mutations and expression of the p53 gene in rat bladder carcinomas and cell lines. Mol. Carcinog., 9, 236-244.
38. Gannon, J. V., Greaves, R., Iggo, R. and Lane, D. P. (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J., 9, 1595-1602.
39. Yang, J. and Duerksen-Hughes, P. (1998) A new approach to identifying genotoxic carcinogens: p53 induction as an indicator of genotoxic damage. Carcinogenesis, 19, 1117-1125.
40. Hartmann, A. and Speit, G. (1996) Effect of arsenic and cadmium on the persistence of mutagen-induced DNA lesions in human cells. Environ. Mol. Mutagen., 27, 98-104.
41. Ho, I. C., Yih, L. H., Kao, C. Y. and Lee, T. C. (2000) Tin-protoporphyrin potentiates arsenite-induced DNA strand breaks, chromatid breaks and kinetochore-negative micronuclei in human fibroblasts. Mutat. Res., 452, 41-50.
42. Mouron, S. A., Golijow, C. D. and Dulout, F. N. (2001) DNA damage by cadmium and arsenic salts assessed by the single cell gel electrophoresis assay. Mutat. Res., 498, 47-55.
43. Sordo, M., Herrera, L. A., Ostrosky-Wegman, P. and Rojas, E. (2001) Cytotoxic and genotoxic effects of As, MMA, and DMA on leukocytes and stimulated human lymphocytes. Teratog. Carcinog. Mutagen., 21, 249-260.
44. Lee, C. H., Chen, J. S., Sun, Y. L., Liao, W. T., Zheng, Y. W., Chai, C. Z., Chen, G. S. and Yu, H. S. (2006) Defective beta1-integrins expression in arsenical keratosis and arsenic-treated cultured human keratinocytes. J. Cutan. Pathol., 33, 129-138.
45. Namgung, U. and Xia, Z. (2000) Arsenite-induced apoptosis in cortical neurons is mediated by c-Jun N-terminal protein kinase 3 and p38 mitogen-activated protein kinase. J. Neurosci., 20, 6442-6451.
46. Sahu, G. R. and Jena, R. K. (2005) Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia. Am. J. Hematol., 78, 113-116.
47. Sidhu, J. S., Ponce, R. A., Vredevoogd, M. A., Yu, X., Gribble, E., Hong, S. W., Schneider, E. and Faustman, E. M. (2006) Cell cycle inhibition by sodium arsenite in primary embryonic rat midbrain neuroepithelial cells. Toxicol. Sci., 89, 475-484.
48. Hartmann, A., Pfuhler, S., Dennog, C., Germadnik, D., Pilger, A. and Speit, G. (1998) Exercise-induced DNA effects in human leukocytes are not accompanied by increased formation of 8-hydroxy-2′-deoxyguanosine or induction of micronuclei. Free Radic. Biol. Med., 24, 245-251.
49. Kizilian-Martel, N., Wilkins, R. C., McLean, J. R., Malone, S. and Raaphorst, G. P. (2003) Prediction of radiosensitivity by measurement of X-ray induced apoptosis in human blood using the comet assay. Anticancer Res., 23, 3847-3854.
50. Linfor, J. J. and Meyers, S. A. (2002) Detection of DNA damage in response to cooling injury in equine spermatozoa using single-cell gel electrophoresis. J. Androl., 23, 107-113.
51. Tran, H. M., Shi, G., Li, G., Carney, J. P., O'Malley, B. and Li, D. (2004) Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer. Otolaryngol. Head Neck Surg., 131, 477-484.
52. Merk, O., Reiser, K. and Speit, G. (2000) Analysis of chromate-induced DNA-protein crosslinks with the comet assay. Mutat. Res., 471, 71-80.
53. Rosa, R. M., do Nascimento Picada, J., Saffi, J. and Henriques, J. A. (2007) Cytotoxic, genotoxic, and mutagenic effects of diphenyl diselenide in Chinese hamster lung fibroblasts. Mutat. Res., 628, 87-98.
54. Wang, J. J., Sanderson, B. J. and Wang, H. (2007) Cytotoxicity and genotoxicity of ultrafine crystalline SiO2 particulate in cultured human lymphoblastoid cells. Environ. Mol. Mutagen., 48, 151-157.
55. Hei, T. K., Liu, S. X. and Waldren, C. (1998) Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc. Natl Acad. Sci. USA, 95, 8103-8107.
56. Huang, R. N., Ho, I. C., Yih, L. H. and Lee, T. C. (1995) Sodium arsenite induces chromosome endoreduplication and inhibits protein phosphatase activity in human fibroblasts. Environ. Mol. Mutagen., 25, 188-196.
57. Lynn, S., Lai, H. T., Gurr, J. R. and Jan, K. Y. (1997) Arsenite retards DNA break rejoining by inhibiting DNA ligation. Mutagenesis, 12, 353-358.
58. Yager, J. W. and Wiencke, J. K. (1997) Inhibition of poly(ADP-ribose) polymerase by arsenite. Mutat. Res., 386, 345-351.
59. Yih, L. H. and Lee, T. C. (1999) Effects of exposure protocols on induction of kinetochore-plus and -minus micronuclei by arsenite in diploid human fibroblasts. Mutat. Res., 440, 75-82.
60. Yih, L. H. and Lee, T. C. (2000) Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res., 60, 6346-6352.
61. Komarova, E. A., Zelnick, C. R., Chin, D., Zeremski, M., Gleiberman, A. S., Bacus, S. S. and Gudkov, A. V. (1997) Intracellular localization of p53 tumor suppressor protein in gamma-irradiated cells is cell cycle regulated and determined by the nucleus. Cancer Res., 57, 5217-5220.
62. Huang, C., Ma, W. Y., Li, J., Goranson, A. and Dong, Z. (1999) Requirement of Erk, but not JNK, for arsenite-induced cell transformation. J. Biol. Chem., 274, 14595-14601.
63. Lau, A. T., Li, M., Xie, R., He, Q. Y. and Chiu, J. F. (2004) Opposed arsenite-induced signaling pathways promote cell proliferation or apoptosis in cultured lung cells. Carcinogenesis, 25, 21-28.
64. Liao, W. T., Chang, K. L., Yu, C. L., Chen, G. S., Chang, L. W. and Yu, H. S. (2004) Arsenic induces human keratinocyte apoptosis by the FAS/FAS ligand pathway, which correlates with alterations in nuclear factor-kappa B and activator protein-1 activity. J. Invest. Dermatol., 122, 125-129.
65. Salazar, A. M., Ostrosky-Wegman, P., Menendez, D., Miranda, E., Garcia-Carranca, A. and Rojas, E. (1997) Induction of p53 protein expression by sodium arsenite. Mutat. Res., 381, 259-265.
66. Ko, L. J. and Prives, C. (1996) p53: puzzle and paradigm. Genes Dev., 10, 1054-1072.
67. Mack, D. H., Vartikar, J., Pipas, J. M. and Laimins, L. A. (1993) Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature, 363, 281-283.
68. Seto, E., Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J. and Shenk, T. (1992) Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 89, 12028-12032.
69. Subbaramaiah, K., Altorki, N., Chung, W. J., Mestre, J. R., Sampat, A. and Dannenberg, A. J. (1999) Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem., 274, 10911-10915.
70. Hsu, C. H., Yang, S. A., Wang, J. Y., Yu, H. S. and Lin, S. R. (1999) Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br. J. cancer, 80, 1080-1086.
71. Shibata, A., Ohneseit, P. F., Tsai, Y. C., Spruck, C. H., III, Nichols, P. W., Chiang, H. S., Lai, M. K. and Jones, P. A. (1994) Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan. Carcinogenesis, 15, 1085-1087.
72. Buckman, S. Y., Gresham, A., Hale, P., Hruza, G., Anast, J., Masferrer, J. and Pentland, A. P. (1998) COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis, 19, 723-729.
73. Trouba, K. J. and Germolec, D. R. (2004) Micromolar concentrations of sodium arsenite induce cyclooxygenase-2 expression and stimulate p42/44 mitogen-activated protein kinase phosphorylation in normal human epidermal keratinocytes. Toxicol. Sci., 79, 248-257.
74. Tsai, S. H., Liang, Y. C., Chen, L., Ho, F. M., Hsieh, M. S. and Lin, J. K. (2002) Arsenite stimulates cyclooxygenase-2 expression through activating IkappaB kinase and nuclear factor kappaB in primary and ECV304 endothelial cells. J. Cell. Biochem., 84, 750-758.
75. Gebel, T. W. (2001) Genotoxicity of arsenical compounds. Int. J. Hyg. Environ. Health, 203, 249-262.
76. Zeng, Q., McCauley, L. K. and Wang, C. Y. (2002) Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression. J. Biol. Chem., 277, 50137-50142.
77. Choi, E. M., Kwak, S. J., Kim, Y. M., Ha, K. S., Kim, J. I., Lee, S. W. and Han, J. A. (2005) COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells. Exp. Mol. Med., 37, 199-203.
78. Lin, M. T., Lee, R. C., Yang, P. C., Ho, F. M. and Kuo, M. L. (2001) Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem., 276, 48997-49002.
79. Nzeako, U. C., Guicciardi, M. E., Yoon, J. H., Bronk, S. F. and Gores, G. J. (2002) COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology, 35, 552-559.
80. Tang, X., Sun, Y. J., Half, E., Kuo, M. T. and Sinicrope, F. (2002) Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res., 62, 4903-4908.
81. Gridley, G., McLaughlin, J. K., Ekbom, A., Klareskog, L., Adami, H. O., Hacker, D. G., Hoover, R. and Fraumeni, J. F., Jr (1993) Incidence of cancer among patients with rheumatoid arthritis. J. Natl Cancer Inst., 85, 307-311.
82. Steinbach, G., Lynch, P. M., Phillips, R. K. et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342, 1946-1952.